Literature DB >> 1910692

The cell biology of antigen processing and presentation.

F M Brodsky1, L E Guagliardi.   

Abstract

Histocompatibility molecules are peptide-binding proteins and present antigenic peptides to T cells. In spite of similarity in structure and peptide specificity, class-I and class-II histocompatibility molecules present peptides at different intracellular locations. Class-I molecules present peptides derived from endogenous proteins, but class-II molecules can present peptides from endocytosed (exogenous) antigen as well as endogenous antigen. Binding of antigenic peptides by histocompatibility molecules is a function of their assembly, intracellular trafficking, and endocytosis. For class-I molecules, assembly appears to be the most important step for peptide acquisition, while all three processes can potentially influence class-II antigen presentation. The versatility of peptide binding by class-II MHC molecules is due to its association with the invariant chain which blocks peptide binding during the initial stages of class-II assembly and export and contributes to the endosomal targeting of class-II molecules. Once invariant chain dissociates, class-II molecules become competent to bind peptides and are released to the cell surface. The location in which a particular antigenic peptide is produced is a function both of its route of introduction into the cell and its susceptibility to degradation. These factors contribute significantly to whether an antigen will be presented by class-I or class-II molecules and should be taken into account in the design and development of vaccines.

Mesh:

Substances:

Year:  1991        PMID: 1910692     DOI: 10.1146/annurev.iy.09.040191.003423

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  69 in total

1.  Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens.

Authors:  J Karttunen; S Sanderson; N Shastri
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

Review 2.  The immunologic properties of epidermal Langerhans cells as a part of the dendritic cell system.

Authors:  N Romani; G Schuler
Journal:  Springer Semin Immunopathol       Date:  1992

3.  Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules.

Authors:  L D Falo; L J Colarusso; B Benacerraf; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

Review 4.  Approaches toward peptide-based immunotherapy of autoimmune diseases.

Authors:  L Adorini; J C Guéry; S Trembleau
Journal:  Springer Semin Immunopathol       Date:  1992

5.  Constitutive endocytosis and recycling of major histocompatibility complex class II glycoproteins in human B-lymphoblastoid cells.

Authors:  P A Reid; C Watts
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

6.  Heterozygosity at individual amino acid sites: extremely high levels for HLA-A and -B genes.

Authors:  P W Hedrick; T S Whittam; P Parham
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

7.  Feline atopic dermatitis. A model for Langerhans cell participation in disease pathogenesis.

Authors:  P J Roosje; D Whitaker-Menezes; M H Goldschmidt; P F Moore; T Willemse; G F Murphy
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

8.  Cloning of the gene encoding peptide-binding protein 74 shows that it is a new member of the heat shock protein 70 family.

Authors:  S Z Domanico; D C DeNagel; J N Dahlseid; J M Green; S K Pierce
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

9.  Molecular basis of genetic polymorphism in major histocompatibility complex-linked proteasome gene (Lmp-2).

Authors:  P Zhou; H Cao; M Smart; C David
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

10.  Domain specificity of the human antibody response to Bacillus anthracis protective antigen.

Authors:  Donald C Reason; Anuska Ullal; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.